Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC/CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

VISN 1 MIRECC Staff: Mehmet Sofuoglu, M.D., Ph.D.

Return to VISN 1 New England MIRECC Staff page

Mehmet Sofuoglu, M.D., Ph.D.



Dr. Mehmet Sofuoglu received his Doctorate of Medicine in 1986 from Hacettepe University in Turkey, and he received his Ph.D. in Pharmacology from the University of Minnesota in 1991. He completed his residency in psychiatry at the University of Minnesota and Stanford University in 1995. He has been a MIRECC Investigator since 2001. In 2006, he became the Co-Director of the VISN 1 New England MIRECC and in 2012 became the Director. He is a Professor of Psychiatry at Yale University. Dr. Sofuoglu's long-term goal is to develop medications for stimulant addiction including cocaine, amphetamines, and nicotine. His research bridges the gap between human laboratory studies examining the medical safety and potential efficacy of new medications for substance dependence and outpatient trials directly examining these medications in drug relapse. Current projects include: 

  • A clinical trial testing the efficacy of galantamine, a cognitive enhancer, as a treatment for cocaine dependence.
  • A pilot clinical trial testing the safety and efficacy of minocycline, a microglia activation inhibitor, as a treatment for hyperalgesia in opioid maintained patients.
  • A human laboratory study examining the reinforcing threshold and dose-response curves for IV nicotine self-administration in male and female smokers with or without nicotine dependence.
  • A human laboratory study examining the reinforcing effects of menthol in combination with IV nicotine in smokers.
  • A clinical trial testing the efficacy of galantamine, a cholinesterase inhibitor, for smoking cessation.

Contact

Mehmet Sofuoglu, M.D., Ph.D.
Director
203-937-4809
Mehmet.Sofuoglu@va.gov

Patricia Sweeney, Psy.D., CPRP
Director for Education
781-687-3015
Patricia.Sweeney@va.gov

Richard Carson, LCSW
Administrative Officer
203-932-5711 Ext. 4338
Richard.Carson@va.gov

Ilan Harpaz-Rotem, Ph.D.
Co-Director for MIRECC Fellowship Program
203-932-5711 Ext. 2599
Ilan.Harpaz-Rotem@va.gov

Suzanne Decker, Ph.D.
Co-Director for MIRECC Fellowship Program
203-932-5711 Ext. 7425
Suzanne.Decker@va.gov